AV-101 vs Esketamine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Reported efficacy
Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)
Result source: NCT02484456
Esketamine · Spravato
Marketed by Johnson & Johnson
NCT02417064 · Phase 3 · completed
The study randomized 346 participants to double-blind 56 mg esketamine, 84 mg esketamine, or matching placebo, each with an oral antidepressant, and used the clinical MADRS depression score at Day 28 as its primary endpoint. The statistical analysis plan tested the 84 mg dose first and allowed a formal test of the 56 mg dose only if 84 mg was significant. The 84 mg dose did not separate from placebo (MMRM p=0.088), so the primary endpoint was missed. The 56 mg difference from placebo (LS mean -4.1 points) was outside the formal testing sequence and counts as nominal only.
Next expected readout: April 2027 · NCT06278779 (registry estimate)
Reported efficacy
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase); Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis (Baseline up to Endpoint (Double-blind Induction Phase [Day 28])): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88) (met)
Result source: NCT02418585
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AV-101 | Esketamine |
|---|---|---|
| MADRS, change (acute) | 30.4 vs 28.6+1.8 vs placeboNCT024844565 other results
| -15.7 vs -12.4−3.3 vs placeboNCT0309713364 other results
|
| CGI-S, change (acute) | —Not reported | -2 vs -1−1 vs placeboNCT0241706430 other results
|
| MADRS response | —Not reported | 53.1% vs 38.9%+14.2 vs placeboNCT0241706467 other results
|
| MADRS remission | —Not reported | 27.1% vs 17.6%vs Quetiapine Extended Release (XR) + Oral ADNCT0433832167 other results
|
| Relapse (% of patients) | —Not reported | —Trial running · NCT07153406 |
MADRS, change (acute)
- AV-101
- 30.4 vs 28.6+1.8 vs placeboNCT02484456
5 other results
- 29.9 vs 30.8 NCT02484456
- 29.5 vs 29.8 NCT02484456
- 28.8 vs 28.8 NCT02484456
- 29.7 vs 27.1 NCT02484456
- 29.3 vs 29.5 NCT02484456
- Esketamine
- -15.7 vs -12.4−3.3 vs placeboNCT03097133
64 other results
- -16.4 vs -12.8 NCT03039192
- -18.8 vs -14.8 NCT02417064
- -17.4 vs -14.3 NCT02417064
- -19 vs -14.8 NCT02417064
- -18.3 vs -14.3 NCT02417064
- -21.4 vs -17 NCT02418585
- -19.6 vs -16.3 NCT02418585
- -10.1 vs -8.1 NCT03434041
- -10 vs -6.3 NCT02422186
- -9.3 vs -5.6 NCT02422186
- -20.1 vs -17.4 NCT03097133
- -19.7 vs -17.4 NCT03039192
- -17.7 vs -15.7 NCT03097133
- -19.1 vs -14.5 NCT03039192
- -21.3 vs -19.5 NCT03097133
- -21.8 vs -19 NCT03039192
- -16 vs -12.4 NCT03097133
- -16.4 vs -12.9 NCT03039192
- -13.5 vs -10.9 NCT03039192
- -23.4 vs -20 NCT03097133
- -22.3 vs -20.4 NCT03039192
- -23.1 vs -21.4 NCT03097133
- -23.9 vs -21.4 NCT03039192
- -24.5 vs -22 NCT03097133
- -24 vs -21.6 NCT03039192
- -29.5 vs -25.8 NCT03039192
- -8 vs -4.4 NCT03434041
- -5.3 vs -3.7 NCT04338321
- -9 vs -6.1 NCT04338321
- -9 vs -5.8 NCT04338321
- -12.8 vs -9.8 NCT04338321
- -12.6 vs -8.9 NCT04338321
- -14.9 vs -12.2 NCT04338321
- -14.5 vs -10.7 NCT04338321
- -16.4 vs -14.3 NCT04338321
- -15.7 vs -12 NCT04338321
- -18.2 vs -16.2 NCT04338321
- -16.9 vs -12.8 NCT04338321
- -18.4 vs -16.7 NCT04338321
- -17.1 vs -13.1 NCT04338321
- -19 vs -17.1 NCT04338321
- -17.6 vs -13.2 NCT04338321
- -19.6 vs -17.8 NCT04338321
- -18.1 vs -13.7 NCT04338321
- -13.4 vs -9.1 NCT02133001
- -13.9 vs -7 NCT04599855
- -15.1 vs -15.3 NCT02918318
- -12.7 vs -7 NCT04599855
- -15.3 vs -4.9 NCT01998958
- -14.5 vs -15.3 NCT02918318
- -15.2 vs -15.3 NCT02918318
- -11.4 vs -4.5 NCT01998958
- -12.4 vs -4.9 NCT01998958
- -10.3 vs -4.9 NCT01998958
- -8.9 vs -4.5 NCT01998958
- -9.8 vs -4.9 NCT01998958
- -7.6 vs -4.5 NCT01998958
- -4.8 vs -4.9 NCT01998958
- -1.2 vs -4.5 NCT01998958
- -6.6 vs -4.5 NCT01998958
- -19.3 vs -12.8 NCT02133001
- -13 vs -9.7 NCT04599855
- -26.4 vs -23 NCT02133001
- -13.9 vs -9.7 NCT04599855
CGI-S, change (acute)
- AV-101
- —Not reported
- Esketamine
- -2 vs -1−1 vs placeboNCT02417064
30 other results
- -2 vs -1 NCT02417064
- -2 vs -2 NCT02418585
- -1 vs -1 NCT03434041
- -2.1 vs -1.9 NCT04338321
- -1.9 vs -1.4 NCT04338321
- -1.9 vs -1.7 NCT04338321
- -1.8 vs -1.3 NCT04338321
- -1.7 vs -1.4 NCT04338321
- -1.6 vs -1.2 NCT04338321
- -1.3 vs -1 NCT04338321
- -1.3 vs -0.9 NCT04338321
- -1 vs -0.7 NCT04338321
- -1 vs -0.7 NCT04338321
- -0.7 vs -0.5 NCT04338321
- -0.7 vs -0.5 NCT04338321
- -0.3 vs -0.2 NCT04338321
- -1 vs 0 NCT02422186
- -1 vs -1 NCT02918318
- -1 vs -1 NCT02918318
- -1 vs -1 NCT02918318
- 4 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 3 vs 5 NCT01998958
- 5 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 4 vs 5 NCT01998958
- 3 vs 5 NCT01998958
MADRS response
- AV-101
- —Not reported
- Esketamine
- 53.1% vs 38.9%+14.2 vs placeboNCT02417064
67 other results
- 47.8% vs 37.2% NCT02417064
- 54.1% vs 38.9% NCT02417064
- 53% vs 37.2% NCT02417064
- 63.4% vs 49.5% NCT02418585
- 6.5% vs 1.6% NCT03434041
- 19.3% vs 16% NCT03434041
- 10.5% vs 6.4% NCT02418585
- 7.9% vs 4.6% NCT02418585
- 23.9% vs 12.5% NCT02422186
- 66.7% vs 63.6% NCT02133001
- 43.6% vs 37.5% NCT02918318
- 20.5% vs 29.7% NCT02918318
- 15% vs 18.2% NCT02918318
- 9.8% vs 3.8% NCT02918318
- 10% vs 9% NCT02918318
- 54.3% vs 29% NCT02133001
- 25.7% vs 12.9% NCT02133001
- 35.3% vs 37.5% NCT02918318
- 13.9% vs 29.7% NCT02918318
- 8.3% vs 18.2% NCT02918318
- 2.6% vs 3.8% NCT02918318
- 13.2% vs 9% NCT02918318
- 33.3% vs 37.5% NCT02918318
- 23.1% vs 29.7% NCT02918318
- 17.5% vs 18.2% NCT02918318
- 2.4% vs 3.8% NCT02918318
- 22% vs 9% NCT02918318
- 30% vs 15.4% NCT01998958
- 25% vs 15.4% NCT01998958
- 41.7% vs 6.1% NCT01998958
- 20% vs 0% NCT01998958
- 41.7% vs 3% NCT01998958
- 40% vs 0% NCT01998958
- 58.3% vs 18.2% NCT01998958
- 40% vs 16.7% NCT01998958
- 9.1% vs 15.4% NCT01998958
- 22.2% vs 15.4% NCT01998958
- 9.1% vs 15.4% NCT01998958
- 22.2% vs 15.4% NCT01998958
- 18.2% vs 6.1% NCT01998958
- 22.2% vs 6.1% NCT01998958
- 0% vs 0% NCT01998958
- 27.3% vs 3% NCT01998958
- 44.4% vs 3% NCT01998958
- 11.1% vs 0% NCT01998958
- 36.4% vs 18.2% NCT01998958
- 44.4% vs 18.2% NCT01998958
- 22.2% vs 16.7% NCT01998958
- 12.5% vs 15.4% NCT01998958
- 12.5% vs 15.4% NCT01998958
- 9.1% vs 6.1% NCT01998958
- 12.5% vs 0% NCT01998958
- 36.4% vs 3% NCT01998958
- 54.5% vs 18.2% NCT01998958
- 33.3% vs 0% NCT01998958
- 0% vs 0% NCT01998958
- 0% vs 16.7% NCT01998958
- 0% vs 0% NCT01998958
- 12.5% vs 16.7% NCT01998958
- 18.2% vs 15.4% NCT01998958
- 18.2% vs 15.4% NCT01998958
- 18.2% vs 6.1% NCT01998958
- 0% vs 0% NCT01998958
- 36.4% vs 3% NCT01998958
- 80% vs 0% NCT01998958
- 36.4% vs 18.2% NCT01998958
- 60% vs 16.7% NCT01998958
MADRS remission
- AV-101
- —Not reported
- Esketamine
- 27.1% vs 17.6%vs Quetiapine Extended Release (XR) + Oral ADNCT04338321
67 other results
- 36.8% vs 32.7% NCT03097133
- 36.6% vs 22.3% NCT03039192
- 25.4% vs 28.3% NCT03097133
- 37.5% vs 26.8% NCT03039192
- 31.6% vs 25.7% NCT03097133
- 33.9% vs 25.9% NCT03039192
- 28.1% vs 23% NCT03097133
- 29.5% vs 23.2% NCT03039192
- 24.6% vs 20.4% NCT03097133
- 26.8% vs 20.5% NCT03039192
- 22.8% vs 17.7% NCT03097133
- 25% vs 11.6% NCT03039192
- 21.9% vs 10.6% NCT03097133
- 18.8% vs 8.9% NCT03039192
- 10.7% vs 8% NCT03039192
- 38.8% vs 30.6% NCT02417064
- 35.4% vs 29.2% NCT02417064
- 36% vs 30.6% NCT02417064
- 34.8% vs 29.2% NCT02417064
- 48.2% vs 30.3% NCT02418585
- 12.8% vs 10.4% NCT03434041
- 15.5% vs 6.3% NCT02422186
- 23.1% vs 20.8% NCT02918318
- 7.7% vs 14.9% NCT02918318
- 10% vs 3.9% NCT02918318
- 4.9% vs 1.3% NCT02918318
- 7.5% vs 3.8% NCT02918318
- 11.8% vs 20.8% NCT02918318
- 5.6% vs 14.9% NCT02918318
- 2.8% vs 3.9% NCT02918318
- 0% vs 1.3% NCT02918318
- 0% vs 3.8% NCT02918318
- 23.1% vs 20.8% NCT02918318
- 10.3% vs 14.9% NCT02918318
- 7.5% vs 3.9% NCT02918318
- 2.4% vs 1.3% NCT02918318
- 9.8% vs 3.8% NCT02918318
- 25% vs 3% NCT01998958
- 20% vs 0% NCT01998958
- 25% vs 0% NCT01998958
- 20% vs 0% NCT01998958
- 25% vs 3% NCT01998958
- 40% vs 16.7% NCT01998958
- 9.1% vs 3% NCT01998958
- 22.2% vs 3% NCT01998958
- 0% vs 0% NCT01998958
- 18.2% vs 0% NCT01998958
- 33.3% vs 0% NCT01998958
- 0% vs 0% NCT01998958
- 18.2% vs 3% NCT01998958
- 33.3% vs 3% NCT01998958
- 0% vs 16.7% NCT01998958
- 9.1% vs 3% NCT01998958
- 12.5% vs 0% NCT01998958
- 36.4% vs 0% NCT01998958
- 0% vs 0% NCT01998958
- 27.3% vs 3% NCT01998958
- 0% vs 0% NCT01998958
- 0% vs 0% NCT01998958
- 12.5% vs 16.7% NCT01998958
- 18.2% vs 3% NCT01998958
- 0% vs 0% NCT01998958
- 27.3% vs 0% NCT01998958
- 80% vs 0% NCT01998958
- 36.4% vs 3% NCT01998958
- 0% vs 16.7% NCT01998958
- 60% vs 16.7% NCT01998958
Relapse (% of patients)
- AV-101
- —Not reported
- Esketamine
- —Trial running · NCT07153406
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AV-101: 2 of 4 rows · Esketamine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | AV-101 | Esketamine |
|---|---|---|
| Dropout rate | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | —84 mga NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 show 75 more results—84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 16.4%84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 5.1%56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —DB Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —FU Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 15.5%Intranasal Esketamine (Esk) Plus O NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —Esketamine Nasal Spray (IND Phase) NCT02782104 · Phase 3 · monotherapy —Esketamine Nasal Spray (OP/MA Phas NCT02782104 · Phase 3 · monotherapy —84 mg NCT04599855 · Phase 4 —OL Treatment: Esketamine 84 mg to NCT04599855 · Phase 4 —56 mg NCT04599855 · Phase 4 —OL Treatment: Esketamine 56 mg to NCT04599855 · Phase 4 —OL Treatment: Placebo to Esketamin NCT04599855 · Phase 4 —Esketamine + Oral AD NCT04829318 · Phase 4 · registry result, not featured evidence · combination 19.1%Esketamine Nasal Spray + Oral Anti NCT04829318 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT04338321 · Phase 3 · registry result, not featured evidence · combination —Double-blind: Intranasal Esketamin NCT03434041 · Phase 3 · registry result, not featured evidence · combination —Follow-up: Intranasal Esketamine+ NCT03434041 · Phase 3 · registry result, not featured evidence · combination 14.3%Intranasal Esketamine + Oral Antid NCT03434041 · Phase 3 · registry result, not featured evidence · combination 29.6%84 mg NCT03097133 · Phase 3 · registry result, not featured evidence 26.3%84 mg NCT03039192 · Phase 3 · registry result, not featured evidence —FU: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —IND: Intranasal Esketamine + Oral NCT02493868 · Phase 3 · registry result, not featured evidence · combination 37.5%Intranasal Esketamine + Oral AD NCT02493868 · Phase 3 · registry result, not featured evidence · combination —MA: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —OP: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —FU: Intranasal Esketamine + Oral A NCT02497287 · Phase 3 · registry result, not featured evidence · combination —IND: Intranasal Esketamine + Oral NCT02497287 · Phase 3 · registry result, not featured evidence · combination 25.5%Intranasal Esketamine + Oral Antid NCT02497287 · Phase 3 · registry result, not featured evidence · combination —OP/MA: Intranasal Esketamine + Ora NCT02497287 · Phase 3 · registry result, not featured evidence · combination —DB Phase: Intranasal Esketamine + NCT02422186 · Phase 3 · registry result, not featured evidence · combination —Follow-up Phase: Intranasal Esketa NCT02422186 · Phase 3 · registry result, not featured evidence · combination 13.9%Intranasal Esketamine Plus Oral An NCT02422186 · Phase 3 · registry result, not featured evidence · combination —84 mg NCT03185819 · Phase 2 · registry result, not featured evidence 8.3%84 mg NCT03185819 · Phase 2 · registry result, not featured evidence —84 mg NCT03185819 · Phase 2 · registry result, not featured evidence —56 mg NCT03185819 · Phase 2 · registry result, not featured evidence 6.5%56 mg NCT03185819 · Phase 2 · registry result, not featured evidence —56 mg NCT03185819 · Phase 2 · registry result, not featured evidence —28 mg NCT03185819 · Phase 2 · registry result, not featured evidence 0%28 mg NCT03185819 · Phase 2 · registry result, not featured evidence —28 mg NCT03185819 · Phase 2 · registry result, not featured evidence —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence 4.9%84 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence 17.5%56 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence 4.9%28 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 25%84 mg NCT02133001 · Phase 2 · registry result, not featured evidence —84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 0%84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence 27.3%28 mg NCT01998958 · Phase 2 · registry result, not featured evidence —28 mg NCT01998958 · Phase 2 · registry result, not featured evidence —28 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —Esketamine/Esketamine/Open Label E NCT01998958 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | —84 mga NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 show 75 more results—84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 6%84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 0.9%56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —DB Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —FU Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 7.8%Intranasal Esketamine (Esk) Plus O NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —Esketamine Nasal Spray (IND Phase) NCT02782104 · Phase 3 · monotherapy —Esketamine Nasal Spray (OP/MA Phas NCT02782104 · Phase 3 · monotherapy —84 mg NCT04599855 · Phase 4 —OL Treatment: Esketamine 84 mg to NCT04599855 · Phase 4 —56 mg NCT04599855 · Phase 4 —OL Treatment: Esketamine 56 mg to NCT04599855 · Phase 4 —OL Treatment: Placebo to Esketamin NCT04599855 · Phase 4 —Esketamine + Oral AD NCT04829318 · Phase 4 · registry result, not featured evidence · combination 3.3%Esketamine Nasal Spray + Oral Anti NCT04829318 · Phase 4 · registry result, not featured evidence · combination 1.2% NCT04338321 · Phase 3 · registry result, not featured evidence · combination —Double-blind: Intranasal Esketamin NCT03434041 · Phase 3 · registry result, not featured evidence · combination —Follow-up: Intranasal Esketamine+ NCT03434041 · Phase 3 · registry result, not featured evidence · combination 5.6%Intranasal Esketamine + Oral Antid NCT03434041 · Phase 3 · registry result, not featured evidence · combination 0%84 mg NCT03097133 · Phase 3 · registry result, not featured evidence 2.6%84 mg NCT03039192 · Phase 3 · registry result, not featured evidence —FU: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —IND: Intranasal Esketamine + Oral NCT02493868 · Phase 3 · registry result, not featured evidence · combination 5%Intranasal Esketamine + Oral AD NCT02493868 · Phase 3 · registry result, not featured evidence · combination —MA: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —OP: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination —FU: Intranasal Esketamine + Oral A NCT02497287 · Phase 3 · registry result, not featured evidence · combination —IND: Intranasal Esketamine + Oral NCT02497287 · Phase 3 · registry result, not featured evidence · combination 6.7%Intranasal Esketamine + Oral Antid NCT02497287 · Phase 3 · registry result, not featured evidence · combination —OP/MA: Intranasal Esketamine + Ora NCT02497287 · Phase 3 · registry result, not featured evidence · combination —DB Phase: Intranasal Esketamine + NCT02422186 · Phase 3 · registry result, not featured evidence · combination —Follow-up Phase: Intranasal Esketa NCT02422186 · Phase 3 · registry result, not featured evidence · combination 5.6%Intranasal Esketamine Plus Oral An NCT02422186 · Phase 3 · registry result, not featured evidence · combination —84 mg NCT03185819 · Phase 2 · registry result, not featured evidence 0%84 mg NCT03185819 · Phase 2 · registry result, not featured evidence —84 mg NCT03185819 · Phase 2 · registry result, not featured evidence —56 mg NCT03185819 · Phase 2 · registry result, not featured evidence 0%56 mg NCT03185819 · Phase 2 · registry result, not featured evidence —56 mg NCT03185819 · Phase 2 · registry result, not featured evidence —28 mg NCT03185819 · Phase 2 · registry result, not featured evidence 0%28 mg NCT03185819 · Phase 2 · registry result, not featured evidence —28 mg NCT03185819 · Phase 2 · registry result, not featured evidence —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence 4.9%84 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence 10%56 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence 2.4%28 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence —84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 13.9%84 mg NCT02133001 · Phase 2 · registry result, not featured evidence —84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 0%84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —84 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence —56 mg NCT01998958 · Phase 2 · registry result, not featured evidence 9.1%28 mg NCT01998958 · Phase 2 · registry result, not featured evidence —28 mg NCT01998958 · Phase 2 · registry result, not featured evidence —28 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —14 mg NCT01998958 · Phase 2 · registry result, not featured evidence —Esketamine/Esketamine/Open Label E NCT01998958 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.3%1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result5.3%1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 0%84 mga NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 show 75 more results3.8%84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —84 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 1.7%56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 4.3%56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —56 mg NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 0.9%DB Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 2.9%FU Phase: Intranasal Esk + Oral AD NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 —Intranasal Esketamine (Esk) Plus O NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 1.1%Esketamine Nasal Spray (IND Phase) NCT02782104 · Phase 3 · monotherapy 19.1%Esketamine Nasal Spray (OP/MA Phas NCT02782104 · Phase 3 · monotherapy 1.7%84 mg NCT04599855 · Phase 4 0%OL Treatment: Esketamine 84 mg to NCT04599855 · Phase 4 1%56 mg NCT04599855 · Phase 4 3%OL Treatment: Esketamine 56 mg to NCT04599855 · Phase 4 2.5%OL Treatment: Placebo to Esketamin NCT04599855 · Phase 4 6%Esketamine + Oral AD NCT04829318 · Phase 4 · registry result, not featured evidence · combination —Esketamine Nasal Spray + Oral Anti NCT04829318 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT04338321 · Phase 3 · registry result, not featured evidence · combination 2.4%Double-blind: Intranasal Esketamin NCT03434041 · Phase 3 · registry result, not featured evidence · combination 1.9%Follow-up: Intranasal Esketamine+ NCT03434041 · Phase 3 · registry result, not featured evidence · combination —Intranasal Esketamine + Oral Antid NCT03434041 · Phase 3 · registry result, not featured evidence · combination 4.4%84 mg NCT03097133 · Phase 3 · registry result, not featured evidence 3.5%84 mg NCT03039192 · Phase 3 · registry result, not featured evidence 0.6%FU: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination 3%IND: Intranasal Esketamine + Oral NCT02493868 · Phase 3 · registry result, not featured evidence · combination —Intranasal Esketamine + Oral AD NCT02493868 · Phase 3 · registry result, not featured evidence · combination 2.6%MA: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination 2.4%OP: Intranasal Esketamine + Oral A NCT02493868 · Phase 3 · registry result, not featured evidence · combination 2.2%FU: Intranasal Esketamine + Oral A NCT02497287 · Phase 3 · registry result, not featured evidence · combination 2.2%IND: Intranasal Esketamine + Oral NCT02497287 · Phase 3 · registry result, not featured evidence · combination —Intranasal Esketamine + Oral Antid NCT02497287 · Phase 3 · registry result, not featured evidence · combination 6.3%OP/MA: Intranasal Esketamine + Ora NCT02497287 · Phase 3 · registry result, not featured evidence · combination 4.2%DB Phase: Intranasal Esketamine + NCT02422186 · Phase 3 · registry result, not featured evidence · combination 0%Follow-up Phase: Intranasal Esketa NCT02422186 · Phase 3 · registry result, not featured evidence · combination —Intranasal Esketamine Plus Oral An NCT02422186 · Phase 3 · registry result, not featured evidence · combination 4.3%84 mg NCT03185819 · Phase 2 · registry result, not featured evidence —84 mg NCT03185819 · Phase 2 · registry result, not featured evidence 33.3%84 mg NCT03185819 · Phase 2 · registry result, not featured evidence 22.6%56 mg NCT03185819 · Phase 2 · registry result, not featured evidence —56 mg NCT03185819 · Phase 2 · registry result, not featured evidence 27.6%56 mg NCT03185819 · Phase 2 · registry result, not featured evidence 13.8%28 mg NCT03185819 · Phase 2 · registry result, not featured evidence —28 mg NCT03185819 · Phase 2 · registry result, not featured evidence 34.5%28 mg NCT03185819 · Phase 2 · registry result, not featured evidence 4.3%84 mg NCT02918318 · Phase 2 · registry result, not featured evidence 2.5%84 mg NCT02918318 · Phase 2 · registry result, not featured evidence —84 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on 0%84 mg NCT02918318 · Phase 2 · registry result, not featured evidence 0%56 mg NCT02918318 · Phase 2 · registry result, not featured evidence 0%56 mg NCT02918318 · Phase 2 · registry result, not featured evidence —56 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on 0%56 mg NCT02918318 · Phase 2 · registry result, not featured evidence 0%28 mg NCT02918318 · Phase 2 · registry result, not featured evidence 2.4%28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —28 mg NCT02918318 · Phase 2 · registry result, not featured evidence · add on 0%28 mg NCT02918318 · Phase 2 · registry result, not featured evidence —flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence 4.2%flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence 2.1%flexible dose NCT02918318 · Phase 2 · registry result, not featured evidence 11.4%84 mg NCT02133001 · Phase 2 · registry result, not featured evidence —84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 3.7%84 mg NCT02133001 · Phase 2 · registry result, not featured evidence 0%84 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%84 mg NCT01998958 · Phase 2 · registry result, not featured evidence 2.4%84 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%56 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%56 mg NCT01998958 · Phase 2 · registry result, not featured evidence 2.6%56 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%28 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%28 mg NCT01998958 · Phase 2 · registry result, not featured evidence 8.3%28 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%14 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%14 mg NCT01998958 · Phase 2 · registry result, not featured evidence 0%14 mg NCT01998958 · Phase 2 · registry result, not featured evidence 2.2%Esketamine/Esketamine/Open Label E NCT01998958 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1,080 mg for 1 Week headache 26.3% (placebo 15.8%) insomnia 15.8% (placebo 10.5%) musculoskeletal pain 15.8% (placebo 15.8%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result1,440 mg for 1 Week abdominal discomfort 5.3% (placebo 10.5%) asthenia 5.3% (placebo 0%) cold sweat 5.3% (placebo 0%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 84 mga nausea 31.9% (placebo 10.6%) dissociation 27.6% (placebo 3.5%) dizziness 22.4% (placebo 8.8%) NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 show 59 more results84 mg headache 3.8% (placebo 16.8%) diarrhoea 1.9% (placebo 2.7%) dizziness 1.9% (placebo 8.8%) NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 56 mg dizziness 27.8% (placebo 8.8%) nausea 27% (placebo 10.6%) dissociation 26.1% (placebo 3.5%) NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 56 mg headache 8.5% (placebo 16.8%) nausea 4.3% (placebo 10.6%) anxiety 2.1% (placebo 6.2%) NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 dissociation 26.1% (placebo 3.7%) nausea 26.1% (placebo 6.4%) vertigo 26.1% (placebo 2.8%) NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 upper respiratory tract infection 8.8% (placebo 0.9%) decreased appetite 5.9% (placebo 2.8%) headache 5.9% (placebo 17.4%) NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3 84 mg dissociation 26.4% (placebo 2.8%) nausea 26.4% (placebo 8.4%) dizziness 22.3% (placebo 7.2%) NCT04599855 · Phase 4 dissociation 14.3% (placebo 2.8%) nausea 14.3% (placebo 8.4%) headache 10.5% (placebo 8.8%) NCT04599855 · Phase 4 56 mg nausea 22.9% (placebo 8.4%) dissociation 21.9% (placebo 2.8%) dizziness 21% (placebo 7.2%) NCT04599855 · Phase 4 nausea 18.2% (placebo 8.4%) headache 13.1% (placebo 8.8%) dissociation 12.1% (placebo 2.8%) NCT04599855 · Phase 4 nausea 29.1% (placebo 8.4%) dizziness 19% (placebo 7.2%) dissociation 17.7% (placebo 2.8%) NCT04599855 · Phase 4 headache 44.3% dizziness 27.3% nasopharyngitis 20.2% NCT04829318 · Phase 4 · registry result, not featured evidence · combination dizziness 46.7% nausea 29.3% dissociation 28.1% NCT04338321 · Phase 3 · registry result, not featured evidence · combination dizziness 77% (placebo 19.8%) dissociation 59.5% (placebo 6.3%) nausea 42.1% (placebo 13.5%) NCT03434041 · Phase 3 · registry result, not featured evidence · combination headache 2.8% (placebo 11.1%) insomnia 2.8% (placebo 8.7%) anxiety 1.9% (placebo 2.4%) NCT03434041 · Phase 3 · registry result, not featured evidence · combination 84 mg dizziness 41.2% (placebo 18.6%) dissociation 38.6% (placebo 8%) nausea 33.3% (placebo 14.2%) NCT03097133 · Phase 3 · registry result, not featured evidence 84 mg dizziness 35.4% (placebo 8.9%) dissociation 29.2% (placebo 3.6%) nausea 20.4% (placebo 13.4%) NCT03039192 · Phase 3 · registry result, not featured evidence headache 1.7% (placebo 0%) anxiety 0.4% (placebo 0%) nausea 0.4% (placebo 1.6%) NCT02493868 · Phase 3 · registry result, not featured evidence · combination vertigo 22.7% (placebo 0%) dizziness 22.2% (placebo 1.6%) nausea 21.5% (placebo 1.6%) NCT02493868 · Phase 3 · registry result, not featured evidence · combination dysgeusia 27% (placebo 0%) vertigo 25% (placebo 0%) dissociation 23% (placebo 0%) NCT02493868 · Phase 3 · registry result, not featured evidence · combination vertigo 20% (placebo 0%) dysgeusia 17.4% (placebo 0%) dissociation 16% (placebo 0%) NCT02493868 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 2% headache 1.1% upper respiratory tract infection 0.8% NCT02497287 · Phase 3 · registry result, not featured evidence · combination dizziness 29.3% dissociation 23.4% nausea 20.2% NCT02497287 · Phase 3 · registry result, not featured evidence · combination dizziness 22.4% headache 18.9% dissociation 18.7% NCT02497287 · Phase 3 · registry result, not featured evidence · combination dizziness 20.8% nausea 18.1% blood pressure increased 12.5% NCT02422186 · Phase 3 · registry result, not featured evidence · combination constipation 8.3% anxiety 0% blood pressure increased 0% NCT02422186 · Phase 3 · registry result, not featured evidence · combination 84 mg dizziness 69.6% (placebo 42.9%) nausea 56.5% (placebo 17.5%) dissociation 47.8% (placebo 17.5%) NCT03185819 · Phase 2 · registry result, not featured evidence 84 mg intentional self-injury 33.3% (placebo 19%) depression 19% (placebo 3.2%) anxiety 14.3% (placebo 15.9%) NCT03185819 · Phase 2 · registry result, not featured evidence 56 mg dizziness 51.6% (placebo 42.9%) nausea 48.4% (placebo 17.5%) headache 41.9% (placebo 28.6%) NCT03185819 · Phase 2 · registry result, not featured evidence 56 mg headache 24.1% (placebo 28.6%) anxiety 13.8% (placebo 15.9%) diarrhoea 10.3% (placebo 4.8%) NCT03185819 · Phase 2 · registry result, not featured evidence 28 mg dizziness 55.2% (placebo 42.9%) dissociation 41.4% (placebo 17.5%) dysgeusia 34.5% (placebo 23.8%) NCT03185819 · Phase 2 · registry result, not featured evidence 28 mg headache 34.5% (placebo 28.6%) intentional self-injury 24.1% (placebo 19%) insomnia 13.8% (placebo 12.7%) NCT03185819 · Phase 2 · registry result, not featured evidence 84 mg headache 4.3% (placebo 0%) muscular weakness 4.3% (placebo 1.9%) nasopharyngitis 4.3% (placebo 5.7%) NCT02918318 · Phase 2 · registry result, not featured evidence 84 mg dissociation 55% (placebo 0%) blood pressure increased 47.5% (placebo 0%) dizziness 37.5% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence 84 mg nasopharyngitis 11.8% (placebo 5.7%) anxiety 5.9% (placebo 0%) asthenia 5.9% (placebo 0%) NCT02918318 · Phase 2 · registry result, not featured evidence 56 mg dizziness 3.4% (placebo 1.9%) nasopharyngitis 3.4% (placebo 5.7%) vomiting 3.4% (placebo 0%) NCT02918318 · Phase 2 · registry result, not featured evidence 56 mg blood pressure increased 46.3% (placebo 0%) dizziness 43.9% (placebo 1.9%) somnolence 31.7% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence 56 mg nasopharyngitis 18.2% (placebo 5.7%) agitation 9.1% (placebo 0%) albuminuria 9.1% (placebo 0%) NCT02918318 · Phase 2 · registry result, not featured evidence 28 mg nasopharyngitis 7.4% (placebo 5.7%) anxiety 3.7% (placebo 0%) dizziness 3.7% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence 28 mg dissociation 34.1% (placebo 0%) blood pressure increased 29.3% (placebo 0%) dizziness 26.8% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence 28 mg nasopharyngitis 15.4% (placebo 5.7%) conjunctivitis allergic 7.7% (placebo 0%) dizziness 7.7% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence flexible dose nasopharyngitis 4.2% (placebo 5.7%) dizziness postural 2.1% (placebo 0%) hypoaesthesia 2.1% (placebo 0%) NCT02918318 · Phase 2 · registry result, not featured evidence flexible dose dissociation 64.6% (placebo 0%) blood pressure increased 50% (placebo 0%) dizziness 43.8% (placebo 1.9%) NCT02918318 · Phase 2 · registry result, not featured evidence 84 mg nausea 37.1% (placebo 3.2%) dizziness 34.3% (placebo 12.9%) dissociation 31.4% (placebo 12.9%) NCT02133001 · Phase 2 · registry result, not featured evidence 84 mg insomnia 11.1% (placebo 6.5%) dry mouth 7.4% (placebo 0%) headache 7.4% (placebo 25.8%) NCT02133001 · Phase 2 · registry result, not featured evidence 84 mg dizziness 41.7% (placebo 1.9%) dissociation 25% (placebo 1.9%) dissociative disorder 25% (placebo 0%) NCT01998958 · Phase 2 · registry result, not featured evidence 84 mg dizziness 29.4% (placebo 1.9%) dysgeusia 23.5% (placebo 16.7%) dissociative disorder 17.6% (placebo 0%) NCT01998958 · Phase 2 · registry result, not featured evidence 84 mg headache 9.5% (placebo 7.4%) decreased appetite 2.4% (placebo 0%) nasopharyngitis 2.4% (placebo 1.9%) NCT01998958 · Phase 2 · registry result, not featured evidence 56 mg dizziness 35% (placebo 1.9%) dissociation 30% (placebo 1.9%) nausea 25% (placebo 9.3%) NCT01998958 · Phase 2 · registry result, not featured evidence 56 mg dizziness 34.4% (placebo 1.9%) dissociation 25% (placebo 1.9%) somnolence 15.6% (placebo 5.6%) NCT01998958 · Phase 2 · registry result, not featured evidence 56 mg nasopharyngitis 12.8% (placebo 1.9%) asthenia 2.6% (placebo 0%) decreased appetite 2.6% (placebo 0%) NCT01998958 · Phase 2 · registry result, not featured evidence 28 mg dizziness 36.4% (placebo 1.9%) headache 36.4% (placebo 7.4%) dysgeusia 18.2% (placebo 16.7%) NCT01998958 · Phase 2 · registry result, not featured evidence 28 mg dizziness 12.5% (placebo 1.9%) headache 12.5% (placebo 7.4%) blood pressure diastolic increased 6.3% (placebo 0%) NCT01998958 · Phase 2 · registry result, not featured evidence 28 mg arthropod bite 8.3% (placebo 0%) bladder pain 8.3% (placebo 0%) blood pressure increased 8.3% (placebo 1.9%) NCT01998958 · Phase 2 · registry result, not featured evidence 14 mg feeling abnormal 18.2% (placebo 1.9%) headache 18.2% (placebo 7.4%) somnolence 18.2% (placebo 5.6%) NCT01998958 · Phase 2 · registry result, not featured evidence 14 mg feeling abnormal 25% (placebo 1.9%) hypoaesthesia 18.8% (placebo 0%) dizziness 12.5% (placebo 1.9%) NCT01998958 · Phase 2 · registry result, not featured evidence 14 mg headache 25% (placebo 7.4%) insomnia 25% (placebo 1.9%) abdominal pain 0% (placebo 0%) NCT01998958 · Phase 2 · registry result, not featured evidence dizziness 30.4% (placebo 1.9%) dysgeusia 19.6% (placebo 16.7%) dissociation 17.4% (placebo 1.9%) NCT01998958 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 67 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
AV-101
show 5 more results
show 5 more results
show 5 more results
Esketamine
show 39 more results
show 3 more results
show 67 more results
show 67 more results
show 30 more results
show 16 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 17 more results
+ 158 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-101's landscape · Esketamine's landscape